Pertuzumab: a step forward in treating HER2-positive breast cancer
Dimitriοs Mavroudis · Translational Cancer Research · 2012
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Translational Cancer Research · AME Publishing Company · article · 2012
Abstract
HER2-positive breast cancer represents an aggressive subtype of the disease occurring in approximately 20% of patients. While trastuzumab has revolutionized the treatment of HER2-positive breast cancer, a proportion of patients have de novo trastuzumab-resistant disease and even those who initially respond will eventually develop trastuzumab-resistance. The recent publication in the New England Journal of Medicine of the promising results of the CLEOPATRA trial for the combination of pertuzumab plus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer (MBC) represented a significant advancement in the treatment of this illness (1).
Open the resolved locator · 10.21037/377
Metadata licence: OpenAlex metadata (CC0)